Drug intelligence / Profile preview

plecanatide

Development stage
Approved
Lead developer
Synergy Pharmaceuticals
Modality
Small Molecules, Peptides
Administration
Oral
01

Overview

Plecanatide is a synthetic 16-amino acid peptide structurally related to human uroguanylin and functions as a guanylate cyclase-C (GC-C) agonist. It is approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Plecanatide acts locally on the luminal surface of intestinal epithelial cells, activating GC-C receptors in a pH-sensitive manner. This activation increases intracellular cyclic guanosine monophosphate (cGMP), which stimulates secretion of chloride and bicarbonate into the intestinal lumen via activation of the cystic fibrosis transmembrane conductance regulator (CFTR). The resulting increase in intestinal fluid softens stool and accelerates transit through the gastrointestinal tract. Plecanatide is minimally absorbed systemically, with its effects localized to the GI tract.

Brand names
TrulancePlectide
Other names
plecanatide
02

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on plecanatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on plecanatide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call